C-Suite Quick Takes: OIS Goes Behind the Scenes with Four Emerging Biotech Companies

OIS Podcast host Carey Powers caught up with four ophthalmology execs and one principal investigator to talk about some of the most exciting developments in retina R&D. Her guests include: • Houman David Hemmati, MD, PhD, Cofounder and Chief Medical Officer of Optigo Biotherapeutics • Michael Tsipursky, MD, CEO and Cofounder of Revive Biotech • Michael Singer, MD, Clinical Professor of Ophthalmology at University of Texas Health Science Center, Director of Clinical Research at Medical Center Ophthalmology Associates, and Principal Investigator for Unity Biotechnology’s BEHOLD trial • Samarendra Mohanty, PhD, President and Cofounder; and Sulagna Bhattacharya, CEO and Cofounder of Nanoscope Therapeutics Optigo is developing binders intended to extend the duration of top-performing intravitreal drugs without compromising efficacy. The company has already had promising results in clinical trials with aflibercept. What’s next? Revive Biotech focuses on central retinal artery occlusion. Its products work by injecting oxygen-loaded nanobubbles into the eye intravitreally. Preclinical studies have advanced through proof of concept. Nanobubbles? Dr. Singer is a principal investigator in Unity Biotechnology’s clinical trial for UBX-1325, a therapeutic in development to treat diabetic macular edema and wet AMD. If approved, the product could work as an adjunct to anti-VEGF therapies. Nanoscope Therapeutics is developing gene therapies that focus on ambient light-sensitive molecules to treat inherited and acquired retinal diseases. Its lead product, MCO-010, is moving through Phase II trials. Why ambient light? Tune in to hear today’s experts discuss: • How Optigo plans to extend the duration of aflibercept • The impact of extending duration activity on patients, physicians, and payers • What Optigo plans to accomplish over the next 12 months What’s behind Revive Biotech’s proprietary technology and what makes it unique. • The milestones it has completed so far with relation to clinical trials, intellectual property, and funding • The new class of therapeutics being developed by Unity Biotechnology •The data released so far on the UBX-1325 BEHOLD trial • If approved, the impact of UBX-1325—an agent that may potentially extend the life of anti-VEGF therapies—on clinical practice • The potential impact of Nanoscope Therapeutics’s MCO-010 on patient communities • The feedback reported from clinical trial participants • The critical milestones Nanoscope Therapeutics intends to achieve over the next year [Listen Now] Resources Optigo Biotherapeutics: https://www.optigobio.com Revive Biotech: https://revivebiotech.com Medical Center Ophthalmology: https://mcoaeyecare.com Unity Biotechnology: https://unitybiotechnology.com Nanoscope Therapeutics: https://nanostherapeutics.com Carey Powers: ois.net/carey-powers Check out episode #378 for quick takes with CEOs from OcuTerra, Neurotech, Notal Vision, and InFocus Clinical Research. https://ois.net/ceo-quick-takes-ois-c... Website: https://ois.net FOLLOW Ophthalmology Innovation Source On Social Media: ► LinkedIn:   / ois-net   ► Twitter:   / oistweets   JOIN Our Group For Ophthalmology Innovation & Investment On LinkedIn   / 2189664   SUBSCRIBE To Our Weekly OIS Newsletter http://bit.ly/2yFOXUt VIEW Our Past Ophthalmology Event Conferences: https://ois.net/past-events REGISTER For Our Next Meeting: https://ois.net/2023-ois-events #OIS #Ophthalmology #Healthcare #Ophthalmic #Medicalinnovation #Retina #Eyediseases _________________________________________________________________ About OIS Ophthalmology Innovation Summit (OIS) facilitates meaningful interactions and the exchange of information between clinical, capital, and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs. Since 2009, the Ophthalmology Innovation Summit programs are independently produced conferences presented annually by Healthegy, Inc.